Dawn Atwell v. Boston Scientific Corporation

740 F.3d 1160
CourtCourt of Appeals for the Eighth Circuit
DecidedNovember 18, 2013
Docket99-2705
StatusPublished
Cited by25 cases

This text of 740 F.3d 1160 (Dawn Atwell v. Boston Scientific Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eighth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dawn Atwell v. Boston Scientific Corporation, 740 F.3d 1160 (8th Cir. 2013).

Opinion

LOKEN, Circuit Judge.

In the Class Action Fairness Act of 2005 (“CAFA”), Congress permitted removal from state to federal court of certain class actions, including “mass actions.” 28 U.S.C. §§ 1332(d), 1453(a) and (b). “[T]he term ‘mass action’ means any civil action ... in which monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that the plaintiffs’ claims involve common questions of law or fact,” § 1332(d)(ll)(B)(i), but does not include an action in which “the claims have been consolidated or coordinated solely for pretrial proceedings,” § 1332(d)(ll)(B)(ii)(IV).

Groups of plaintiffs filed product liability actions in Missouri’s Twenty-Second (City of St. Louis) Judicial Circuit against four manufacturers of transvaginal mesh medical devices. Three groups included claims against Boston Scientific Corporation for alleged defects in its devices. 1 Each group comprised less than 100 plaintiffs. The three groups filed similar motions proposing that the state court assign each group “to a single Judge for purposes of discovery and trial.” After the motion hearing, Boston Scientific removed the three cases to federal court. Two district judges granted plaintiffs’ motions and remanded the cases to state court on the ground that no case included more than 100 plaintiffs *1162 and plaintiffs had not proposed to the state court that the actions be “tried jointly.” Boston Scientific petitions for permission to appeal, arguing that the three groups of plaintiffs have proposed to try their cases jointly within the meaning of 28 U.S.C. § 1332(d)(ll)(B)(i), transforming their cases into a single mass action subject to federal jurisdiction. Reviewing this issue de novo, see Raskas v. Johnson & Johnson, 719 F.3d 884, 886 (8th Cir.2013), we conclude we have jurisdiction and, in each case, grant Boston Scientific leave to appeal and vacate the order remanding the case to state court.

I. Two Jurisdictional Issues

A. Most orders remanding removed cases to state court are not appealable. 28 U.S.C. § 1447(d). CAFA created an exception to that rule, permitting a court of appeals to review an order remanding a “class action,” including a mass action, “if application [to appeal] is made ... not more than 10 days after entry of the [remand] order,” § 1453(c)(1). Atwell argues we have no jurisdiction because these cases are not mass actions and therefore CAFA does not apply. This argument of course begs the question. The issue presented on appeal is whether the three cases are a mass action subject to federal jurisdiction under CAFA. If they are a mass action, then CAFA confers appellate jurisdiction to correct the district court errors in declining to accept federal jurisdiction. If they are not a mass action, then “we lack jurisdiction to proceed further.” Anderson v. Bayer Corp., 610 F.3d 390, 394 (7th Cir.2010) (emphasis added).

B. Evans and Taylor argue that Boston Scientific failed to file timely notices of removal. When a plaintiffs initial pleading does not state a case that is removable under CAFA — which was true here because each case involves claims by fewer than 100 persons — the defendant must file a notice of removal “within 30 days after receipt by the defendant ... of a copy of an amended pleading, motion, order or other paper from which it may first be ascertained that the ease is one which is or has become removable.” 28 U.S.C. § 1446(b)(3).

Evans and Taylor argue their state court motions for assignment to a single judge gave sufficient notice the cases had become removable; therefore, Boston Scientific’s notices of removal, filed nearly five months later, were untimely. We disagree. The thirty-day time limit begins running when a plaintiff “explicitly discloses” she is seeking a remedy that affords a basis for federal jurisdiction. Knudson v. Sys. Painters, Inc., 634 F.3d 968, 974 (8th Cir.2011). Here, plaintiffs’ assignment motions attempted to limit their request to coordination of pretrial proceedings, which would keep the cases outside the definition of a mass action. See 28 U.S.C. § 1332(d)(U)(B)(ii)(IV). Only when plaintiffs’ attorneys made clear the extent of consolidation being sought at the state court motions hearing did Boston Scientific have a basis for removal. These oral statements, made at a court hearing and later transcribed, like deposition testimony, satisfy § 1446(b)(3)’s “other paper” requirement. See Carvalho v. Equifax Info. Servs., LLC, 629 F.3d 876, 887 (9th Cir.2010); Peters v. Lincoln Elec. Co., 285 F.3d 456, 465-66 (6th Cir.2002).

II. The Merits

Although plaintiffs concede that their respective individual claims “involve common questions of law or fact,” 28 U.S.C. § 1332(d)(ll)(B)(i), state court plaintiffs with common claims against a common defendant may bring separate cases with fewer than 100 plaintiffs each to avoid federal jurisdiction under CAFA— *1163 unless their claims are “proposed to be tried jointly.” See Romo v. Teva Pharm. USA Inc., 731 F.3d 918, 922 & n. 1 (9th Cir.2013); Scimone v. Carnival Corp., 720 F.3d 876, 881-82 (11th Cir.2013); Abrahamsen v. ConocoPhillips, Co., 503 Fed.Appx. 157, 160 (3d Cir.2012), cert. de nied.,—U.S.-, 133 S.Ct. 1820, 185 L.Ed.2d 856 (2013); Anderson, 610 F.3d at 393-94; Tanoh v. Dow Chem. Co., 561 F.3d 945, 953 (9th Cir.), cert. denied 558 U.S. 934, 130 S.Ct. 187, 175 L.Ed.2d 236 (2009). That proviso is the critical issue here — did the distinct claims of these more than 100 plaintiffs, filed in the same court against the same defendant and asserting common issues, become a single, removable mass action because plaintiffs proposed to try their separate cases jointly?

In the Evans and Taylor

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Archer Farms v. UMB Bank, N.A.
N.D. Mississippi, 2025
Jefferson County v. Williams
E.D. Missouri, 2024
Wills v. Stiles
W.D. Missouri, 2023
Brian Adams v. 3M Company
65 F.4th 802 (Sixth Circuit, 2023)
Curtis Morgan v. Dow Chemical Company
879 F.3d 602 (Fifth Circuit, 2018)
Jerry Dunson v. Cordis Corporation
854 F.3d 551 (Ninth Circuit, 2017)
Melissa Ramirez v. Vintage Pharmaceuticals LLC
852 F.3d 324 (Third Circuit, 2017)
Gibson v. Clean Harbors Environmental Services, Inc.
840 F.3d 515 (Eighth Circuit, 2016)
Justine Briggs v. Merck Sharp & Dohme
796 F.3d 1038 (Ninth Circuit, 2015)
Margalit Corber v. Xanodyne Pharmaceuticals, Inc.
771 F.3d 1218 (Ninth Circuit, 2014)
Time Insurance v. Astrazeneca AB
52 F. Supp. 3d 705 (E.D. Pennsylvania, 2014)
Teague v. Johnson & Johnson
749 F.3d 879 (Tenth Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
740 F.3d 1160, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dawn-atwell-v-boston-scientific-corporation-ca8-2013.